Hospital
Berkshire Medical Center, INC
Berkshire Medical Center, INC was paid $150.13M by Medicaid between Jan 2018 and Dec 2024, across 688 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoBERKSHIRE MEDICAL CENTER, INC
PITTSFIELD, MA 01201
PITTSFIELD, MA 01201
33aNPI1295765261assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$150.13M
24GClaims3,855,758
24DCodes billed688
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#11 of 66
Median peer was paid$29.11M
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RODOWICZ, DARLENE controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 533,018 | $25.87M | |
| 2019 | 523,444 | $20.89M | |
| 2020 | 493,389 | $17.85M | |
| 2021 | 606,068 | $22.34M | |
| 2022 | 621,492 | $23.71M | |
| 2023 | 635,494 | $23.78M | |
| 2024incomplete | 442,853 | $15.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 183,622 | 167,937 | $23.75M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.8% | 90,503 | 78,622 | $11.78M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.4% | 57,755 | 48,763 | $6.66M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.8% | 40,695 | 37,836 | $5.74M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.8% | 31,962 | 30,119 | $4.22M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 153,029 | 110,074 | $3.71M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 31,232 | 23,809 | $3.29M |
| 64405 | 2.1% | 12,278 | 10,523 | $3.11M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 13,599 | 13,047 | $2.96M |
| H0010 | Alcohol and/or drug services; sub-acute detoxification (residential addiction program inpatient) | 2.0% | 5,166 | 642 | $2.94M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.7% | 18,272 | 16,612 | $2.63M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.7% | 8,027 | 7,703 | $2.53M |
676 more codes
| H0011 | Alcohol and/or drug services; acute detoxification (residential addiction program inpatient) | 1.6% | 788 | $2.34M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 56,605 | $2.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 6,672 | $1.93M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 4,111 | $1.89M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 16,891 | $1.85M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.2% | 4,388 | $1.82M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 3,410 | $1.76M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 6,784 | $1.64M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,120 | $1.43M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 26,480 | $1.38M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,130 | $1.32M |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 50,682 | $1.08M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 215,816 | $1.01M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,576 | $961K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 10,262 | $956K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 2,113 | $931K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,222 | $925K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 6,116 | $881K |
| 59025 | Fetal non-stress test | <1% | 3,680 | $877K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 26,413 | $866K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25,517 | $863K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25,259 | $854K |
| 80053 | Comprehensive metabolic panel | <1% | 171,257 | $834K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 9,054 | $819K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 8,053 | $812K |
| 20552 | <1% | 10,125 | $798K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,352 | $791K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,265 | $729K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 538 | $714K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,442 | $684K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41,894 | $682K |
| 93971 | <1% | 3,981 | $657K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 67,833 | $657K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,835 | $645K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,657 | $644K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,901 | $643K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 470 | $614K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12,269 | $597K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,249 | $581K |
| 96367 | <1% | 7,126 | $526K | |
| 76801 | <1% | 4,010 | $523K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,880 | $514K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,410 | $499K |
| 64450 | <1% | 6,201 | $483K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,557 | $475K |
| G0378 | Hospital observation service, per hour | <1% | 9,008 | $473K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 1,078 | $465K |
| 97597 | <1% | 7,210 | $440K | |
| 64615 | <1% | 1,573 | $426K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 8,824 | $418K |
| 64493 | <1% | 997 | $402K | |
| 62323 | <1% | 1,306 | $388K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,828 | $374K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 6,371 | $356K |
| 80061 | Lipid panel | <1% | 58,734 | $356K |
| 96127 | <1% | 9,206 | $349K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 20,548 | $346K |
| 99205 | Prolong outpt/office vis | <1% | 2,166 | $336K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,593 | $331K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 9,540 | $329K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,241 | $321K |
| 76642 | <1% | 2,963 | $316K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,105 | $308K |
| 87507 | <1% | 2,242 | $302K | |
| 76775 | <1% | 3,640 | $300K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 518 | $299K |
| 20610 | <1% | 2,671 | $299K | |
| 87070 | <1% | 27,580 | $296K | |
| 20553 | <1% | 4,152 | $293K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,445 | $276K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,300 | $274K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 177 | $270K |
| 76770 | <1% | 1,619 | $266K | |
| 59899 | <1% | 394 | $261K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 10,679 | $261K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 4,741 | $258K |
| 87088 | <1% | 40,182 | $257K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,579 | $253K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,505 | $253K |
| 76830 | Ultrasound, transvaginal | <1% | 3,947 | $250K |
| 71250 | <1% | 4,933 | $249K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13,030 | $248K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51,497 | $247K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,052 | $241K |
| 87486 | <1% | 8,092 | $240K | |
| 88142 | <1% | 12,839 | $234K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,664 | $234K |
| 99223 | Prolong inpt eval add15 m | <1% | 3,272 | $233K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,337 | $233K |
| 58300 | <1% | 941 | $231K | |
| 64483 | <1% | 790 | $231K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 30,975 | $230K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,635 | $223K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16,408 | $223K |
| 94060 | <1% | 2,884 | $218K | |
| 95886 | <1% | 926 | $214K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,229 | $211K |
| 76813 | <1% | 1,402 | $208K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,659 | $206K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 50,312 | $203K |
| 97803 | <1% | 2,575 | $203K | |
| 93017 | <1% | 2,501 | $196K | |
| 82728 | <1% | 21,130 | $190K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,953 | $187K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 5,967 | $184K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 57,893 | $184K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,504 | $179K |
| 76536 | <1% | 1,477 | $177K | |
| 87510 | <1% | 8,951 | $176K | |
| 87660 | <1% | 8,948 | $176K | |
| 86003 | <1% | 1,339 | $176K | |
| 97161 | <1% | 2,976 | $175K | |
| 87480 | <1% | 8,949 | $174K | |
| 72141 | <1% | 721 | $173K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,286 | $170K |
| 84439 | <1% | 28,954 | $169K | |
| 73221 | <1% | 564 | $166K | |
| 12001 | <1% | 881 | $166K | |
| 86803 | <1% | 15,646 | $166K | |
| 84466 | <1% | 19,805 | $165K | |
| 84484 | <1% | 26,020 | $164K | |
| 84703 | <1% | 19,898 | $146K | |
| 83655 | <1% | 7,271 | $145K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,238 | $145K |
| 73030 | <1% | 3,982 | $140K | |
| 87481 | <1% | 3,363 | $140K | |
| 73110 | <1% | 2,606 | $138K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,170 | $137K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,013 | $134K |
| 70486 | <1% | 1,367 | $133K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,792 | $130K |
| 73630 | <1% | 4,440 | $128K | |
| 83690 | <1% | 24,480 | $126K | |
| 83880 | <1% | 10,742 | $122K | |
| 81513 | <1% | 2,853 | $119K | |
| 74018 | <1% | 2,246 | $119K | |
| 77080 | <1% | 4,850 | $118K | |
| 73562 | <1% | 4,328 | $115K | |
| 73610 | <1% | 3,540 | $115K | |
| 72100 | <1% | 2,831 | $113K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 2,187 | $112K |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 118 | $110K |
| 82607 | <1% | 12,866 | $109K | |
| 86618 | <1% | 7,881 | $108K | |
| 86780 | <1% | 9,891 | $108K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,669 | $108K |
| 83605 | <1% | 15,335 | $107K | |
| 90715 | <1% | 3,874 | $105K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,689 | $104K |
| 73130 | <1% | 3,507 | $104K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 1,114 | $103K |
| 83735 | <1% | 27,994 | $103K | |
| 97750 | <1% | 3,819 | $102K | |
| 84702 | <1% | 6,293 | $101K | |
| ATP14 | <1% | 27,818 | $95K | |
| 83970 | <1% | 5,854 | $95K | |
| 87340 | <1% | 9,648 | $93K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 461 | $93K |
| 87625 | <1% | 6,737 | $91K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 455 | $91K |
| 81329 | <1% | 1,015 | $91K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 11,615 | $90K |
| 77065 | Tomosynthesis, mammo | <1% | 1,831 | $89K |
| 87186 | <1% | 14,463 | $87K | |
| 71271 | <1% | 2,670 | $87K | |
| 10060 | <1% | 477 | $86K | |
| 83540 | <1% | 20,431 | $86K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,503 | $86K |
| 70498 | <1% | 784 | $84K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 29,361 | $84K |
| 58301 | <1% | 417 | $84K | |
| 83520 | <1% | 7,205 | $84K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 626 | $82K |
| 84153 | <1% | 6,515 | $81K | |
| 97162 | <1% | 2,074 | $81K | |
| 92567 | <1% | 1,912 | $80K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,540 | $78K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,890 | $75K |
| 98929 | <1% | 2,466 | $75K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 65 | $75K |
| 86141 | <1% | 9,850 | $71K | |
| 86850 | <1% | 8,944 | $70K | |
| 72131 | <1% | 1,887 | $69K | |
| 94729 | <1% | 2,601 | $69K | |
| 76376 | <1% | 45,903 | $67K | |
| 87653 | <1% | 1,965 | $66K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17,056 | $64K |
| 77066 | Tomosynthesis, mammo | <1% | 1,171 | $64K |
| 87902 | <1% | 310 | $64K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 748 | $63K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 231 | $62K |
| 86704 | <1% | 6,907 | $62K | |
| 99406 | <1% | 9,234 | $62K | |
| 86706 | <1% | 7,589 | $62K | |
| 84403 | <1% | 2,872 | $60K | |
| 77062 | <1% | 686 | $60K | |
| 87040 | <1% | 7,790 | $59K | |
| 80076 | <1% | 13,522 | $59K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 486 | $58K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,637 | $58K |
| 57454 | <1% | 157 | $58K | |
| 90686 | <1% | 3,613 | $57K | |
| 88341 | <1% | 2,068 | $57K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,607 | $56K |
| 81000 | <1% | 26,049 | $56K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,068 | $56K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 326 | $56K |
| J3490 | Unclassified drugs | <1% | 3,247 | $53K |
| 86480 | <1% | 1,740 | $53K | |
| 81001 | <1% | 16,357 | $52K | |
| 88342 | <1% | 5,208 | $52K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,882 | $51K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 678 | $51K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 420 | $51K |
| 85610 | <1% | 33,154 | $50K | |
| 73502 | <1% | 2,423 | $50K | |
| 95806 | <1% | 39 | $50K | |
| 86709 | <1% | 6,909 | $49K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,665 | $49K |
| 86762 | <1% | 3,013 | $49K | |
| 85027 | <1% | 10,410 | $48K | |
| 83516 | <1% | 3,213 | $47K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 544 | $46K |
| 77061 | <1% | 507 | $45K | |
| 94726 | <1% | 1,601 | $45K | |
| 84481 | <1% | 4,222 | $45K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 881 | $43K |
| 86787 | <1% | 3,059 | $43K | |
| 29125 | <1% | 273 | $42K | |
| 81508 | <1% | 717 | $41K | |
| 97116 | <1% | 1,753 | $40K | |
| 86140 | <1% | 11,244 | $39K | |
| 87631 | <1% | 517 | $39K | |
| 86038 | <1% | 4,475 | $39K | |
| 93296 | <1% | 2,245 | $37K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 239 | $37K |
| 52000 | <1% | 192 | $37K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 274 | $36K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,221 | $36K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,531 | $36K |
| 81002 | <1% | 22,231 | $36K | |
| 88304 | <1% | 2,409 | $36K | |
| 82746 | <1% | 4,256 | $35K | |
| 0002A | <1% | 821 | $35K | |
| 86765 | <1% | 2,223 | $34K | |
| 76818 | <1% | 159 | $34K | |
| 82784 | <1% | 4,066 | $34K | |
| 99496 | <1% | 703 | $34K | |
| 85652 | <1% | 17,262 | $33K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 66 | $33K |
| 84146 | <1% | 1,732 | $32K | |
| 84425 | <1% | 2,170 | $32K | |
| 98928 | <1% | 1,057 | $32K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 901 | $32K |
| 76942 | <1% | 246 | $31K | |
| ATP08 | <1% | 14,653 | $31K | |
| 84182 | <1% | 1,686 | $31K | |
| 00731 | <1% | 825 | $30K | |
| 85730 | <1% | 9,204 | $30K | |
| 82043 | <1% | 11,397 | $30K | |
| 83001 | <1% | 1,217 | $30K | |
| 0001A | <1% | 694 | $29K | |
| 96376 | <1% | 10,116 | $29K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,101 | $29K |
| 11102 | <1% | 53 | $29K | |
| 82570 | <1% | 11,552 | $28K | |
| 70496 | <1% | 755 | $28K | |
| 85379 | <1% | 3,778 | $28K | |
| 92557 | <1% | 415 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,225 | $28K |
| J2704 | Injection, propofol, 10 mg | <1% | 20,055 | $28K |
| 81025 | <1% | 3,483 | $27K | |
| 82670 | <1% | 791 | $27K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,634 | $27K |
| 96415 | <1% | 595 | $27K | |
| 82105 | <1% | 1,827 | $26K | |
| 86900 | <1% | 8,791 | $26K | |
| 86901 | <1% | 8,721 | $25K | |
| V5266 | Battery for use in hearing device | <1% | 660 | $25K |
| 0003A | <1% | 1,007 | $25K | |
| ATP15 | <1% | 6,541 | $25K | |
| 99408 | <1% | 3,151 | $25K | |
| 99217 | <1% | 728 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,546 | $24K |
| 87205 | <1% | 8,001 | $24K | |
| 85007 | <1% | 10,351 | $23K | |
| 86481 | <1% | 360 | $23K | |
| 80050 | General health panel | <1% | 272 | $23K |
| 84520 | <1% | 10,634 | $23K | |
| 76870 | <1% | 175 | $23K | |
| 73140 | <1% | 396 | $22K | |
| ATP17 | <1% | 15,620 | $22K | |
| 95885 | <1% | 82 | $22K | |
| 87581 | <1% | 722 | $22K | |
| 99219 | <1% | 747 | $22K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $22K |
| 83921 | <1% | 2,174 | $22K | |
| 27096 | <1% | 49 | $21K | |
| 84207 | <1% | 1,048 | $20K | |
| 29581 | <1% | 321 | $20K | |
| 70491 | <1% | 122 | $19K | |
| 99495 | <1% | 515 | $19K | |
| 93299 | <1% | 971 | $19K | |
| 96160 | <1% | 816 | $19K | |
| 93225 | <1% | 368 | $18K | |
| 81003 | <1% | 8,032 | $17K | |
| 99462 | <1% | 407 | $17K | |
| 74183 | <1% | 48 | $17K | |
| 84100 | <1% | 17,912 | $17K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 80 | $17K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,477 | $17K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 23,731 | $16K |
| J0897 | Injection, denosumab, 1 mg | <1% | 150 | $16K |
| 90677 | <1% | 548 | $16K | |
| 80164 | <1% | 3,037 | $16K | |
| 72110 | <1% | 219 | $16K | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 405 | $15K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $15K |
| 86235 | <1% | 438 | $15K | |
| 74019 | <1% | 470 | $15K | |
| 12011 | <1% | 81 | $15K | |
| 84134 | <1% | 1,984 | $15K | |
| 86430 | <1% | 3,066 | $14K | |
| 92587 | <1% | 136 | $14K | |
| 86376 | <1% | 946 | $14K | |
| 99385 | <1% | 182 | $14K | |
| 83525 | <1% | 1,128 | $14K | |
| 91320 | <1% | 200 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 19,586 | $13K |
| 82378 | <1% | 2,231 | $13K | |
| 11981 | <1% | 51 | $13K | |
| 83002 | <1% | 481 | $13K | |
| 97166 | <1% | 186 | $12K | |
| 51705 | <1% | 193 | $12K | |
| 90674 | <1% | 627 | $12K | |
| 76882 | <1% | 113 | $12K | |
| 12002 | <1% | 53 | $12K | |
| 82077 | <1% | 7,921 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,172 | $12K |
| 82150 | <1% | 1,943 | $12K | |
| 82131 | <1% | 536 | $12K | |
| 93923 | <1% | 318 | $12K | |
| 82805 | <1% | 257 | $11K | |
| 87634 | <1% | 275 | $11K | |
| 0124A | <1% | 457 | $11K | |
| 72128 | <1% | 467 | $11K | |
| 73080 | <1% | 370 | $11K | |
| 72040 | <1% | 215 | $11K | |
| 84460 | <1% | 4,208 | $11K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 707 | $11K |
| 94761 | <1% | 379 | $11K | |
| 93970 | <1% | 111 | $11K | |
| 93308 | <1% | 74 | $11K | |
| 82977 | <1% | 2,466 | $11K | |
| 97035 | <1% | 243 | $10K | |
| 82565 | <1% | 5,594 | $10K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 695 | $10K |
| 84132 | <1% | 4,669 | $10K | |
| 83615 | <1% | 6,853 | $10K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 13 | $10K |
| 91200 | <1% | 67 | $10K | |
| 84165 | <1% | 2,444 | $10K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,938 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,917 | $9K |
| 77336 | <1% | 212 | $9K | |
| 86666 | <1% | 344 | $9K | |
| 83721 | <1% | 2,093 | $9K | |
| 93270 | <1% | 186 | $9K | |
| 82550 | <1% | 5,428 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,289 | $9K |
| 86708 | <1% | 772 | $8K | |
| 88307 | <1% | 148 | $8K | |
| 0012A | <1% | 321 | $8K | |
| 00813 | <1% | 174 | $8K | |
| 76857 | <1% | 196 | $8K | |
| 17110 | <1% | 33 | $8K | |
| 84450 | <1% | 3,129 | $8K | |
| 96523 | <1% | 448 | $7K | |
| 51798 | <1% | 2,179 | $7K | |
| 46600 | <1% | 24 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,864 | $7K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,269 | $7K |
| 99460 | <1% | 70 | $7K | |
| 86696 | <1% | 351 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,331 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 677 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,847 | $7K |
| 86316 | <1% | 503 | $7K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 636 | $7K |
| 90656 | <1% | 367 | $7K | |
| 97165 | <1% | 55 | $6K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 27 | $6K |
| V5160 | Dispensing fee, binaural | <1% | 13 | $6K |
| 00812 | <1% | 140 | $6K | |
| 94664 | <1% | 568 | $6K | |
| 90678 | <1% | 46 | $6K | |
| 84550 | <1% | 4,808 | $6K | |
| 93298 | <1% | 247 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 84,100 | $6K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,249 | $6K |
| 86665 | <1% | 202 | $6K | |
| 82040 | <1% | 4,512 | $6K | |
| 82248 | <1% | 2,917 | $6K | |
| 98927 | <1% | 227 | $5K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 398 | $5K |
| 72072 | <1% | 100 | $5K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 6,126 | $5K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 51 | $5K |
| ATP03 | <1% | 6,861 | $5K | |
| 82310 | <1% | 2,544 | $5K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 47 | $5K |
| 0054A | <1% | 249 | $5K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 35 | $5K |
| 90688 | <1% | 381 | $5K | |
| 82533 | <1% | 322 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $5K |
| 82950 | <1% | 763 | $5K | |
| 90480 | <1% | 202 | $5K | |
| ATP09 | <1% | 1,895 | $5K | |
| 99224 | <1% | 114 | $5K | |
| 97163 | <1% | 174 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,226 | $5K |
| 86308 | <1% | 556 | $4K | |
| 64494 | <1% | 1,181 | $4K | |
| 88112 | <1% | 478 | $4K | |
| 97802 | <1% | 56 | $4K | |
| 84156 | <1% | 1,619 | $4K | |
| 84255 | <1% | 172 | $4K | |
| 82785 | <1% | 187 | $4K | |
| 84630 | <1% | 373 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,188 | $4K |
| 99225 | <1% | 90 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,685 | $4K |
| 87536 | <1% | 107 | $4K | |
| 99386 | <1% | 63 | $4K | |
| 82247 | <1% | 1,403 | $4K | |
| 59430 | <1% | 30 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,369 | $4K |
| 73590 | <1% | 169 | $4K | |
| 84270 | <1% | 184 | $4K | |
| 97167 | <1% | 66 | $4K | |
| 86695 | <1% | 240 | $3K | |
| 80179 | <1% | 221 | $3K | |
| ATP07 | <1% | 1,471 | $3K | |
| 86735 | <1% | 264 | $3K | |
| 82947 | <1% | 1,747 | $3K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 2,476 | $3K |
| 62321 | <1% | 12 | $3K | |
| 86256 | <1% | 350 | $3K | |
| 73120 | <1% | 61 | $3K | |
| 36430 | <1% | 18 | $3K | |
| 0053A | <1% | 79 | $3K | |
| 84591 | <1% | 182 | $3K | |
| 00811 | <1% | 103 | $3K | |
| 80178 | <1% | 1,104 | $3K | |
| 86300 | <1% | 494 | $3K | |
| 0031A | <1% | 105 | $3K | |
| ATP02 | <1% | 1,523 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,507 | $3K |
| 86160 | <1% | 121 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,446 | $3K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 5,116 | $3K |
| 90746 | <1% | 53 | $3K | |
| 72193 | <1% | 112 | $3K | |
| ATP11 | <1% | 2,188 | $2K | |
| 90694 | <1% | 458 | $2K | |
| 99152 | <1% | 4,620 | $2K | |
| 99221 | <1% | 45 | $2K | |
| 86200 | <1% | 190 | $2K | |
| 11719 | <1% | 74 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,282 | $2K |
| 90732 | <1% | 242 | $2K | |
| 0134A | <1% | 100 | $2K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 282 | $2K |
| 93880 | <1% | 80 | $2K | |
| 86664 | <1% | 106 | $2K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 99 | $2K |
| 90714 | <1% | 120 | $2K | |
| 86663 | <1% | 106 | $2K | |
| 82140 | <1% | 378 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,687 | $2K |
| 86769 | <1% | 258 | $2K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 723 | $2K |
| 94010 | <1% | 12 | $2K | |
| 87255 | <1% | 49 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 219 | $2K |
| ATP18 | <1% | 1,321 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,092 | $2K |
| 87476 | <1% | 55 | $2K | |
| 99459 | <1% | 934 | $2K | |
| 80329 | <1% | 280 | $2K | |
| 87468 | <1% | 904 | $2K | |
| 93798 | <1% | 80 | $2K | |
| 99407 | <1% | 116 | $1K | |
| ATP16 | <1% | 330 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 452 | $1K |
| 99220 | <1% | 12 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,093 | $1K |
| 80197 | <1% | 1,962 | $1K | |
| 87081 | <1% | 141 | $1K | |
| 0013A | <1% | 66 | $1K | |
| 87338 | <1% | 136 | $1K | |
| 87469 | <1% | 908 | $1K | |
| 82652 | <1% | 39 | $1K | |
| 80143 | <1% | 293 | $1K | |
| 82962 | <1% | 20,333 | $1K | |
| 86360 | <1% | 38 | $1K | |
| 84155 | <1% | 1,994 | $1K | |
| 85384 | <1% | 172 | $1K | |
| 86258 | <1% | 80 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,901 | $1K |
| 11720 | <1% | 81 | $996.11 | |
| 11721 | <1% | 138 | $992.61 | |
| 97168 | <1% | 35 | $977.71 | |
| 73600 | <1% | 33 | $929.43 | |
| 64495 | <1% | 494 | $899.12 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 562 | $891.72 |
| 87210 | <1% | 161 | $871.45 | |
| C1769 | Guide wire | <1% | 583 | $869.63 |
| 86359 | <1% | 38 | $868.56 | |
| 0011A | <1% | 18 | $825.68 | |
| 80361 | <1% | 487 | $766.17 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 451 | $735.59 |
| 80354 | <1% | 2,582 | $728.98 | |
| 74160 | <1% | 129 | $726.12 | |
| 0064A | <1% | 42 | $690.34 | |
| ATP06 | <1% | 356 | $680.12 | |
| 80177 | <1% | 142 | $679.60 | |
| 73564 | <1% | 13 | $677.52 | |
| 96368 | <1% | 37 | $625.79 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 107 | $617.78 |
| 87521 | Neg quan hep c or qual rna | <1% | 16 | $607.67 |
| 99490 | Ccm add 20min | <1% | 554 | $566.47 |
| 86146 | <1% | 13 | $557.04 | |
| V5014 | Repair/modification of a hearing aid | <1% | 14 | $555.00 |
| ATP10 | <1% | 349 | $549.93 | |
| ATP04 | <1% | 201 | $542.77 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 14 | $532.40 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 64 | $512.73 |
| 90651 | <1% | 12 | $506.04 | |
| 84295 | <1% | 572 | $499.54 | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 124 | $434.83 |
| J1815 | Injection, insulin, per 5 units | <1% | 4,908 | $434.20 |
| 90653 | <1% | 130 | $426.94 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 150 | $424.02 |
| 73020 | <1% | 50 | $415.30 | |
| 86800 | <1% | 24 | $406.09 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $404.36 |
| 80348 | <1% | 2,288 | $383.07 | |
| 82627 | <1% | 12 | $378.30 | |
| ATP05 | <1% | 135 | $377.87 | |
| 80051 | <1% | 1,699 | $371.30 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,843 | $358.11 |
| 88313 | <1% | 235 | $353.50 | |
| 96417 | <1% | 144 | $334.65 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 12 | $328.98 |
| 83704 | <1% | 64 | $328.96 | |
| 80346 | <1% | 1,134 | $326.83 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 31 | $323.22 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 377 | $316.93 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,900 | $312.09 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,997 | $309.54 |
| 86617 | <1% | 12 | $280.64 | |
| 84075 | <1% | 482 | $278.82 | |
| 84144 | <1% | 15 | $276.00 | |
| 86658 | <1% | 12 | $275.76 | |
| 86039 | <1% | 28 | $266.35 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 280 | $262.83 |
| 82274 | <1% | 29 | $255.59 | |
| 64484 | <1% | 92 | $254.72 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,587 | $247.37 |
| 86753 | <1% | 24 | $244.06 | |
| 82010 | <1% | 17 | $239.46 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 447 | $232.42 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 71 | $232.08 |
| 84432 | <1% | 12 | $228.94 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 35 | $214.17 |
| 90662 | <1% | 198 | $203.15 | |
| 74220 | <1% | 67 | $193.63 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 621 | $183.03 |
| 73620 | <1% | 15 | $174.55 | |
| 73090 | <1% | 13 | $171.90 | |
| 86225 | <1% | 14 | $169.68 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 240 | $163.84 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,379 | $156.66 |
| 88312 | <1% | 12 | $153.04 | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 31 | $150.50 |
| 99417 | Prolong home eval add 15m | <1% | 12 | $149.60 |
| 95911 | <1% | 14 | $148.47 | |
| 85014 | <1% | 88 | $146.45 | |
| 85018 | <1% | 88 | $146.45 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 152 | $143.13 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 212 | $142.31 |
| 89050 | <1% | 28 | $142.08 | |
| 92591 | <1% | 18 | $139.96 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 649 | $138.67 |
| 90670 | <1% | 24 | $130.82 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 1,797 | $125.49 |
| 86334 | <1% | 51 | $124.99 | |
| 82390 | <1% | 13 | $120.46 | |
| 80156 | <1% | 44 | $118.49 | |
| 99307 | <1% | 26 | $117.54 | |
| 80355 | <1% | 307 | $112.18 | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 20 | $109.08 |
| 99497 | <1% | 648 | $108.66 | |
| 87493 | <1% | 247 | $90.79 | |
| 80365 | <1% | 222 | $87.56 | |
| 85046 | <1% | 41 | $84.99 | |
| 93246 | <1% | 13 | $82.77 | |
| 82374 | <1% | 179 | $79.84 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 97 | $78.37 |
| 87075 | <1% | 15 | $77.76 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 90 | $61.94 |
| 94799 | <1% | 114 | $60.35 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 17 | $59.64 |
| 86364 | <1% | 79 | $58.44 | |
| 81596 | <1% | 40 | $53.90 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 312 | $49.50 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 50 | $48.40 |
| 83550 | <1% | 314 | $46.95 | |
| 86301 | <1% | 205 | $42.90 | |
| 80185 | <1% | 39 | $39.43 | |
| 84154 | <1% | 28 | $37.92 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 287 | $37.36 |
| 86920 | <1% | 15 | $34.72 | |
| 82232 | <1% | 49 | $33.36 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 58 | $30.84 |
| 80162 | <1% | 16 | $27.38 | |
| 80175 | <1% | 13 | $24.18 | |
| 82330 | <1% | 13 | $24.13 | |
| 84145 | <1% | 124 | $24.01 | |
| 82270 | <1% | 16 | $20.16 | |
| 51702 | <1% | 20 | $16.92 | |
| 87150 | <1% | 719 | $16.84 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 271 | $11.54 |
| G0009 | Administration of pneumococcal vaccine | <1% | 841 | $10.61 |
| 82465 | <1% | 40 | $8.32 | |
| 90756 | <1% | 34 | $7.51 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 542 | $6.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 774 | $5.71 |
| S5145 | Foster care, therapeutic, child; per diem | 0% | 24 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 37 | $0.00 |
| 91300 | 0% | 1,401 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 574 | $0.00 |
| 91312 | 0% | 233 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 397 | $0.00 |
| H0041 | Foster care, child, non-therapeutic, per diem | 0% | 61 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 440 | $0.00 |
| 91313 | 0% | 35 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 110 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | 0% | 91 | $0.00 |
| 96402 | 0% | 12 | $0.00 | |
| 80353 | 0% | 69 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 15 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 173 | $0.00 |
| 80324 | 0% | 875 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 104 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 228 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 254 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 191 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 35 | $0.00 |
| 91305 | 0% | 200 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 547 | $0.00 |
| 91301 | 0% | 201 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 263 | $0.00 |
| 74174 | 0% | 13 | $0.00 | |
| 95012 | 0% | 44 | $0.00 | |
| 91303 | 0% | 44 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 57 | $0.00 |
| 80320 | 0% | 54 | $0.00 | |
| C1819 | Surgical tissue localization and excision device (implantable) | 0% | 13 | $0.00 |
| 73501 | 0% | 13 | $0.00 | |
| 91306 | 0% | 14 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODOWICZ, DARLENE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Fairview Hospital | Great Barrington, MA | $17.67M |
| Berkshire Medical Center, INC | Pittsfield, MA | $15.35M |
| Berkshire Faculty Services INC | Pittsfield, MA | $13.13M |
| Fairview Hospital | North Adams, MA | $3.50M |
| Berkshire Medical Center, INC. | Pittsfield, MA | $3.10M |
| Fairview Hospital | Williamstown, MA | $2.82M |
| Fairview Hospital | Great Barrington, MA | $1.95M |
| Berkshire Medical Center, INC | North Adams, MA | $639K |
| North Adams Regional Hospital Corporation | North Adams, MA | $306K |
| BHS Urgent Care Center | Pittsfield, MA | $126K |
| Berkshire Medical Center, INC. | Pittsfield, MA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.